Safety and tolerance of infant formulas containing probiotics: a multicenter, randomised, controlled trial in healthy

M Mitra1, A Petit-Jean2, R Agrawal3

  • 1Department of Pediatrics, Institute of Child Health, Kolkata, India.

Beneficial Microbes
|October 7, 2025
PubMed

Insights

Infant formula with Limosilactobacillus reuteri or Bifidobacterium lactis probiotics showed non-inferior weight gain compared to standard formula. These probiotic formulas were safe and well-tolerated in healthy term infants.

Area of Science:

  • Pediatric Nutrition
  • Microbiome Research
  • Clinical Trials

Background:

  • Probiotic safety and tolerance in infants are documented, primarily with supplements.
  • Limited data exists on probiotics integrated into infant formula for growth evaluation.
  • This study addresses the need for evidence on formula-based probiotics in early life.

Purpose of the Study:

  • To evaluate the non-inferiority of infant growth fed formula supplemented with Limosilactobacillus reuteri DSM17938 or Bifidobacterium lactis CNCM I-3446 compared to standard formula.
  • To assess anthropometric measurements, digestive tolerance, and gut microbiota changes.
  • To confirm the safety and tolerance of these probiotic-supplemented formulas.

Main Methods:

  • Randomized, double-blind, multicenter trial involving healthy term infants.
  • Three formula groups: L. reuteri, B. lactis, and standard formula (n=92 each).
  • Exclusively breastfed infants (n=100) included for reference; mixed feeding allowed.

Main Results:

  • Non-inferior weight gain was observed for both L. reuteri and B. lactis groups compared to the standard formula at 6 months.
  • No significant differences in length, BMI, or head circumference z-scores, except for a slight decrease in weight-for-age z-score for B. lactis at 8 months.
  • Similar adverse events and digestive tolerance reported across all formula groups; higher fecal L. reuteri counts in the L. reuteri group.

Conclusions:

  • Infant formula supplemented with L. reuteri DSM17938 or B. lactis CNCM I-3446 supports non-inferior growth in term infants up to 6 months.
  • Both probiotic formulas demonstrated safety and good tolerance, comparable to standard formula and breastfed infants.
  • These findings support the use of specific probiotics within infant formula for healthy growth and tolerance.

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
126
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
170
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
219
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
261